The Stakes in Wisconsin's Supreme Court Race Are High. Here's Why.
Sorry, Libs, the People Still Support Trump Deporting Illegals
Anti-Gunner Organization Just Made the Case for Trans-Identified People to Own Firearms
Here's What's at Stake for Republicans in Wisconsin's Supreme Court Elections
Iran Loads Up Missiles After Trump Issues Threat
Colorado Far From Finished Infringing on Gun Rights
More 'Extremely Dangerous Criminals' Have Been Sent to El Salvador
Dems Say Wisconsin Is Not for Sale. Walker Hits Them With the Facts.
Trump Applauds Markwayne Mullin's Sunday Show Appearance Delivering Masterclass on 'Signal...
The High Cost of Coastal Litigation: A Threat to Louisiana’s Economy and Trump’s...
DOGE Will Look Into Lawmakers Who Became 'Strangely Wealthy'
Another Poll Shows Democrats in Disarray Over How the Party Is Handling Trump
Trump's Answer to a Question About a Third-Term Is Sure to Trigger the...
Here’s Why the LA Times Is Suing Mayor Karen Bass
Scott Jennings Goes Up Against Former Pentagon Spokesperson on 'Signalgate'
OPINION

West Virginia on the Right Track to Lower Drug Costs, But is it Enough?

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
Advertisement
Advertisement
Advertisement
AP Photo/Matt Rourke

The GOP-controlled House of Delegates in West Virginia recently unanimously passed a bill that would require pharmacy benefit managers (PBM) to share the rebates they receive from drug companies with consumers at the point of purchase. The bill now goes to the state Senate.

Advertisement

Pharmacy benefit managers were created to administer drug benefits for health plans including commercial, employee and retiree plans and Medicare Part D.  In 2003, the PBM industry secured safe harbor status from Congress that exempted them from criminal prosecution for taking rebates from drug manufacturers. 

Essentially, PBMs can collect these kickbacks and give certain medications access to the millions of insured lives they manage over another manufacturer’s products based on how much the companies pay them. The PBMs’ priority shifted from the payer (health plans) to the seller (drug manufacturers) and created a conflict of interest. 

Patients may find the cost of their medications drastically increase due to a change in formulary tiering set by the pharmacy benefit manager. A skewed business practice emerged where PBMs are paid a percentage of the cost of the utilized drugs they manage which increases the compensation they receive for higher-priced drugs. Keep in mind that PBMs do no research and development, manufacturing or distribution. 

The West Virginia bill is admirable in that state legislators want to address the escalating price of prescription drugs and lower the out-of-pocket costs for consumers, but is it enough? AMAC – the Association of Mature Americans, along with a coalition of physician and patient advocates are working together to see the safe harbor status repealed and the middleman money removed completely from the outpatient prescription drug supply chain.

Advertisement

Drug manufacturers’ list prices are negatively affected by the kickbacks they must pay to PBMs. Removing the middleman money and the resulting many billions of dollars saved in drug costs seems like a sensible place to start the forthcoming debate on health care reform.  

Andrew Mangione is Senior Vice President at AMAC Action, the advocacy arm of AMAC – the Association of Mature American Citizens.  AMAC represents more than 2 million members and stands for fiscal responsibility. He writes on health care issues, among other concerns.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos